C013: Zaltrap / Eylea Biosimilar Stable Cell Line (CHO)
The yield of Zaltrap / Eylea biosimilar from the CHO stable cell line was above 2.1 g/L in a 3 liter manufacturing.
C013P: Aflibercept Biosimilar
Recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors fused with the Fc region of human immunoglobulin gamma 1 (IgG1).
Specificity/Sensitivity: The aflibercept biosimilar protein specifically binds to the human VEGF.
Applications: Functional assays, and those assays for studying biological pathways affected by aflibercept.